Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 SCNX | Healthcare | $2.90 | 4.58K | $4.94M | -0.06 | ― | Moderate Buy |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| SCNX | Scienture Holdings | 2.90 | -13.18 | -81.97% |
| Name | Price | % Change | |
|---|---|---|---|
| SCNX | $2.90 | -81.97% |
Scienture Holdings, Inc. (SCNX) is scheduled to report 3rd quarter earnings on 11/12/2026. Regarding Q3 estimates, Wall Street analysts expect Scienture Holdings, Inc. to post earnings of -$1.57 per share.
Scienture Holdings ( ($SCNX) ) has provided an update. On October 28, 2026, Scienture Holdings held its annual meeting of stockholders virtually, with holders representing 14,496,459.75 votes, or 35.3% of
Maxim lowered the firm’s price target on Scienture (SCNX) to $6 from $37.50 and keeps a Buy rating on the shares. The firm cites the company’s below-consensus Q3 revenue pre-announcement
Scienture Holdings ( ($SCNX) ) just unveiled an update. Scienture Holdings, Inc., a Nasdaq-listed specialty pharmaceutical holding company, reported strong commercial momentum in the third quarter of 2026 driven by
The major averages were fractionally lower near noon as investors digest earnings reports from big banks, as well as other major names like UnitedHealth and Domino’s Pizza. Analysts expect S&P
“These preliminary third-quarter revenue results mark a significant inflection point for Scienture (SCNX), demonstrating the accelerating commercial momentum of our expanding pharmaceutical portfolio,” said Narasimhan Mani, president and co-CEO of
Scienture Holdings ( ($SCNX) ) has provided an announcement. Scienture Holdings implemented a 1-for-25 reverse stock split of its common stock, following board approval on September 17, 2026 and effectiveness
These are the upcoming stock splits for the week of October 5 to October 9, based on TipRanks’ Stock Splits Calendar. Stock splits are one of the few places on Wall
Maxim Group analyst Naz Rahman reiterated a Buy rating on Scienture Holdings yesterday and set a price target of $1.50. Naz Rahman has given his Buy rating due to a
19:50 EDT Scienture (SCNX) Holdings Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| SCNX | buy | Reiterated | Oct 23, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| SCNX | Apr 5, 2027TBA | $4.94M | ― | ― | 0.00 | -0.06 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
